Stockholders Approve 2026 Incentive Plan with 9.2% Potential Dilution
MNPR has more than doubled off its 52-week low of $29.18.
Summary
Monopar Therapeutics stockholders approved the 2026 Stock Incentive Plan, which authorizes the issuance of shares that could lead to 9.2% potential dilution.
Key Events · Corporate Governance and Compliance · MNPR
-
Stock Incentive Plan Approved
Stockholders approved the 2026 Stock Incentive Plan, authorizing the company to issue shares for employee incentives.
-
Potential Dilution
The approved plan carries a potential dilution of up to 9.2% if all authorized shares are issued.
-
Director Elections
All six nominated directors were elected to the Board of Directors.
-
Executive Compensation Approved
Stockholders provided advisory approval for the compensation of named executive officers.
Analysis · MNPR · Life Sciences
Monopar Therapeutics stockholders approved the 2026 Stock Incentive Plan, which authorizes the company to issue additional shares for employee compensation. If all shares under this plan are issued, it could result in up to 9.2% dilution for existing shareholders. This finalizes the proposal previously outlined in the DEF 14A filed on April 30, 2026.
How filings like this one have moved
In the 30 days to Sep 15, 2026, 29.9% of the 1678 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.25%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MNPR was trading at $68.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $460M. The 52-week trading range was $29.18 to $105.00. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.